<DOC>
	<DOCNO>NCT01025349</DOCNO>
	<brief_summary>Bevacizumab monoclonal antibody currently use treatment colorectal cancer . It work prevent formation new blood vessel ( angiogenesis ) . The drug show inhibit vascular endothelial growth factor ( VEGF ) activity . Previous research show positive finding solid tumor metastasize . In study , investigator investigate response add bevacizumab conventional chemotherapy metastatic breast cancer patient .</brief_summary>
	<brief_title>Salvage Therapy With Bevacizumab Plus Docetaxel Cisplatin Taiwanese Metastatic Breast Cancer</brief_title>
	<detailed_description>Targeted chemotherapy gradually become mainstay cancer treatment present day . Targeted medication trastuzumab , bevacizumab lapatinib recently extensively adopt many cancer , particularly breast cancer . Among targeted medication , bevacizumab monoclonal antibody act vascular endothelial growth factor receptor work prevent formation new blood vessel ( angiogenesis ) . Published article indicate monotherapy bevacizumab breast cancer show 9-17 % response rate , combine paclitaxel , treatment outcome appear improve progression-free survival objective response rate . We curious additive effect bevacizumab conventional chemotherapy , toxicity induce combined target therapy conventional chemotherapy duration remission treatment could achieve . In study , utilized bevacizumab , docetaxel plus cisplatin metastatic breast cancer patient furthermore , evaluate treatment response , toxicity duration remission main goal .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 . Normal leave ventricular ejection fraction ( LVEF ) . Age ≤ 65 year . At least one unidimensionally measurable lesion image study . AST/ALT 2.5 ULN ( &lt; 5 ULN liver metastasis ) . Serum bilirubin 3 ULN , Serum Creatinine 1.5 ULN . Urine dipstick proteinuria &lt; 2+ . Women childbearing potential must negative serum pregnancy test . Uncontrolled hypertension ( systolic blood pressure &gt; 160 mm Hg , diastolic blood pressure &gt; 90 mm Hg ) . Prior exposure bevacizumab . Planned radiotherapy underlie disease ( prior complete radiotherapy treatment allow ) , except bone metastasis . Evidence bleed diathesis coagulopathy . Clinically significant ( i.e . active ) cardiovascular disease example cerebrovascular accident ( ≤ 6 month ) , myocardial infarction ( ≤ 6 month ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication . Stroke precede six month . Evidence disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use bevacizumab chemotherapy . Ongoing treatment aspirin ( &gt; 325 mg/day ) medication know predispose gastrointestinal ulceration . Pregnancy ( positive serum pregnancy test ) lactation . Any serious uncontrolled illness , opinion investigator , make undesirable patient enter trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>docetaxel</keyword>
</DOC>